Advanced Solid Cancers clinical trials

Explore recruiting advanced solid cancers clinical trials.

Recruiting advanced solid cancers studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Solid Cancers trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Study of Personalized Neoantigen Specific TCR T cells in the Treatment of Advanced Solid Cancers

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation

Italy, Spain, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Advanced Solid Cancers trials by city

Advanced Solid Cancers in Toronto Advanced Solid Cancers in Vancouver Advanced Solid Cancers in Montreal Advanced Solid Cancers in Calgary Advanced Solid Cancers in Edmonton Advanced Solid Cancers in Ottawa Advanced Solid Cancers in Winnipeg Advanced Solid Cancers in Quebec City Advanced Solid Cancers in Hamilton Advanced Solid Cancers in Kitchener Advanced Solid Cancers in London Advanced Solid Cancers in Halifax Advanced Solid Cancers in New York Advanced Solid Cancers in Los Angeles Advanced Solid Cancers in Chicago Advanced Solid Cancers in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease